Journal of Leukocyte Biology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published online as doi:10.1189/jlb.0105023 on June 3, 2005

Published online before print June 3, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0105023v1
78/3/612    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herrmann, J. M.
Right arrow Articles by Van Dyke, T. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herrmann, J. M.
Right arrow Articles by Van Dyke, T. E.
(Journal of Leukocyte Biology. 2005;78:612-619.)
© 2005 by Society for Leukocyte Biology

Simultaneous measurements of cytoplasmic Ca2+ responses and intracellular pH in neutrophils of localized aggressive periodontitis (LAP) patients

Jens Martin Herrmann*,{dagger}, Alpdogan Kantarci*, Heidi Long{dagger}, John Bernardo{dagger}, Hatice Hasturk*, Lewis V. Wray, Jr.{dagger}, Elizabeth R. Simons{dagger} and Thomas E. Van Dyke*,1

* Goldman School of Dental Medicine and
{dagger} School of Medicine, Boston University, Massachusetts

1Correspondence: Department of Periodontology and Oral Biology, Boston University, Goldman School of Dental Medicine, 100 East Newton St., Boston, MA 02118. E-mail: tvandyke{at}bu.edu


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
In view of the reports that polymorphonuclear leukocytes (PMN) of patients with localized aggressive periodontitis (LAP) exhibit hyper-responsiveness to stimulation, it has been suggested that such abnormalities could lead to PMN-mediated tissue damage during inflammation. To determine whether these abnormalities include signal transduction, we compared cytoplasmic calcium concentration ({Delta}[Ca2+]i) and cytoplasmic pH ({Delta}pHi) changes, early stimulus responses to chemotactic agents, of LAP versus control (C)-PMN and explored whether these could be modulated by sensitizing cytokines or calcium channel-blocking agents. PMN responses of LAP patients were compared with age- and gender-matched controls. {Delta}[Ca2+]i and {Delta}pHi were measured fluorimetrically using 1H-indole-6-carboxylic acid, 2-[4-[bis[2-[(acetyloxy)methoxy]-2-oxoethyl]amino]-3-[2-[2-[bis[2-[(acetyloxy)methoxy]-2-oxoethyl]amino]-5-methylphenoxy]ethoxy]phenyl]-1 and 2',7'-bis-(carboxyethyl)-5(6)-carboxyfluorescein as respective probes. Not only was the maximal calcium response to chemoattractants higher in LAP-PMN, but also their subsequent intracellular calcium redistribution was significantly slower. The slower calcium redistribution of LAP-PMN, but not their higher maximal calcium response, was successfully mimicked in C-PMN treated with NifedipineTM or 1-[b-[3-(4-methoxyphenyl)propoxy]-4-methoxyphenethyl]-1H-imidazole-HCl, both known to be inhibitors of membrane-associated calcium influx, but this redistribution was not affected when inhibitors of other calcium influx mechanisms, DiltiazemTM or VerapamilTM, were used. Taken together, our findings indicate that certain early stimulus responses are aberrant in LAP-PMN, that internal redistribution of cytoplasmic-free calcium is compromised, and, additionally, that a membrane-associated Ca2+ transport defect may be present.

Key Words: human polymorphonuclear neutrophils • stimulus responses • spectrofluorimetry


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Localized aggressive periodontitis (LAP) is a severe periodontal disorder, typically peri-pubertal, which affects the supporting tissues of the teeth. The disease is characterized by severe local inflammation associated with the putative periodontal pathogen Actinobacillus actinomycetemcomitans. A typical case begins around the first molars and incisors, a finding that allows LAP to be distinguished clinically from other marginal periodontal infections. Untreated, this disease leads to purulent and rapid dental exfoliation that can elicit systemic complications (for reviews, see refs. [1 2 3 ]).

Severe systemic or unusual infections are often associated with inherited defects of neutrophil function. This may be true for LAP. Furthermore, diseases such as human immunodeficiency virus/AIDS, certain forms of neutropenia or leukemia, and genetically triggered syndromes such as Down’s, Papillon–Lefèvre, Cohen, leukocyte-adhesion deficiency, Chédiak–Higashi, histiocytosis, Ehlers–Danlos, and hypophosphatasia have been related to LAP and should be considered as systemic risk factors (as reviewed by Meyle and Gonzales [4 ]). These disorders are characterized by compromised host responses to infection, particularly in the function of leukocytes, thereby impairing the clearance of oral microbial plaque and aggravating the severity and progression of associated LAP. In addition, local polymorphonuclear leukocyte (PMN) counts at sites affected by periodontal inflammation have been shown to be reduced when, in particular, their innate chemotactic and bactericidal functions are compromised [5 ].

The regulatory mechanisms that control chemotaxis, adhesion, phagocytosis, and oxidative activity involve changes in the cytoplasmic pH (pHi) and cytoplasmic calcium concentration ([Ca2+]i) [6 7 8 9 ]. Several membrane channels, cytoplasmic calcium buffer- and sensor-molecules, as well as subcellular stores control the calcium homeostasis of PMN. When monitored kinetically, the cytoplasmic calcium response to stimulation typically is biphasic: A rapid release from the intracellular stores increases [Ca2+]i to a level tenfold greater than the basal 100 nM and is followed by an influx from the surrounding medium, which re-establishes calcium homeostasis and leaves the free [Ca2+]i at approximately 200 nM [10 ]. These stimulus changes in [Ca2+]i of PMN have been shown to be modulated in part by certain calcium channel inhibitors [11 , 12 ].

Thus, the receptor-controlled mechanisms that dictate PMN function in response to specific stimuli, e.g., upon binding of the chemotactic peptide formyl-Met-Leu-Phe (fMLP), fibroblast-, macrophage-, and PMN-derived interleukin 8 (IL-8), or other ligands to their receptors on the PMN membrane, begin rapidly following engagement of the receptor by its ligand [6 7 8 9 ]. This signal can be propagated through two branches of the inositol phospholipid signaling cascade. In one branch, the receptor triggers the plasma membrane-bound phospholipase C isoforms (typically PLCß) via the activated Gq-{alpha}-subunit. PLCß then cleaves inositol-1,4,5-triphosphate (IP3), leaving diacylglycerol (DAG) on the membrane. Elevated IP3 concentrations then open IP3-gated Ca2+release channels in subcellular stores, mostly in the endoplasmic reticulum. In the other branch, the membrane-bound DAG together with phosphatidylserine and cytoplasmic Ca2+ can activate protein kinase C (PKC). This enzyme has various target proteins, among them various gene regulatory proteins as well as membrane channels themselves.

Various components of these PMN stimulus-response pathways are thought to be compromised in LAP-PMN, including a lower DAG kinase activity [13 ], a diminished PKC activity [14 ], and, recently, lower DAG kinase RNA levels and DAG kinase activity [15 ]. These findings are in concordance with the reports of elevated levels of the PKC activator DAG in LAP-PMN [13 , 16 , 17 ]. More recent reports mention that an additional fMLP-mediated IP3-independent signal propagation, downstream of the receptor–ligand binding signal of the formyl peptide receptor-like 1, through CD38 and activation of the ryanodine receptor at calcium stores, initiates a cytoplasmic calcium response [18 ].

In contrast to PMN from normal controls, Daniel et al. [19 ] reported defective chemotaxis in LAP-PMN and suggested a link between impaired chemotaxis and the altered cytosolic calcium response upon stimulation with fMLP. Additionally, they found the oxidative burst to be elevated in LAP-PMN. Another report implied that the activation of the putative calcium influx factor (CIF) was depressed, providing one possible reason for an altered cytoplasmic calcium response in LAP patients [20 ].

The aim of the present study was to determine whether LAP-PMN exhibit fundamental stimulus-response signaling abnormalities. If they do, their effector functions would probably be affected, and thus, the LAP-PMN could play a role in the disease’s severity and progression. We demonstrate here that the LAP-PMN do indeed exhibit intrinsic differences in their early signaling response to chemoattractants and are undertaking an investigation of their functional responses. Additionally, the impact of commercially available calcium channel inhibitors on the changes in [Ca2+]i ({Delta}[Ca2+]i) and pHi ({Delta}pHi) was tested to determine mechanisms of Ca2+ homeostasis in these cells and whether the abnormal PMN functions can be modulated.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Materials
The membrane-permeable fluorescent probes, 1H-indole-6-carboxylic acid, 2-[4-[bis[2-[(acetyloxy)methoxy]-2-oxoethyl]amino]-3-[2-[2-[bis[2-[(acetyloxy)methoxy]-2-oxoethyl]amino]-5-methylphenoxy]ethoxy]phenyl]-acetoxymethyl ester (Indo-1 AM ) and 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxylmethyl ester (BCECF-AM), were obtained from Molecular Probes (Eugene, OR). Dissolved in dry dimethyl sulfoxide (DMSO) and then aliquotted in glass vacutainers, they were kept frozen at –20°C until ready to use. The Ca2+ channel inhibitor 1-[b-[3-(4-methoxyphenyl)propoxy]-4-methoxyphenethyl]-1H-imidazole-HCP (SKF-96365-HCl) was purchased from EMD/Calbiochem (La Jolla, CA). NifedipineTM and all the other substances came from Fisher Scientific (Pittsburgh, PA) or Sigma-Aldrich (St. Louis, MO). All buffers were prepared with high-pressure liquid chromatography-grade chemicals in our laboratory as described below, using our in-house, deionized water, which was processed additionally in four stages: charcoal, ion exchange, pyrogard filter, and thereafter, distillation. It should be noted that we previously had found it absolutely essential to use water thus purified to avoid possible presensitization of PMN during the isolation process; this can be monitored via resting Ca 2+, [Ca2+]0, which should be ~100 nM [21 ].

Patient characteristics
All patients (LAP) were recruited through the Clinical Research Center at the Boston University School of Dental Medicine (MA); healthy controls (C) were similarly recruited through the dental clinics of the school. The Institutional Review Board of the Boston University School of Medicine approved the study, and all patients and controls gave their written, informed consent for this ex vivo study. Patient samples were obtained when these individuals first came to the clinic, had been suffering from the disease without treatment for at least 2 years, and exhibited the characteristic bone loss patterns of LAP. The clinical diagnosis for LAP was made using the criteria of the American Academy of Periodontology [22 ], and except for the patients’ LAP, all study participants were healthy, as determined by a detailed medical history review. No concomitant medication or systemic condition known to affect the periodontal tissues was detected.

Neutrophil preparation
Whole blood was collected by venipuncture into 15 ml vacutainers containing 1.5 ml of a 4.3% citrate solution. PMN were purified by Dextran sedimentation followed by Ficoll-Hypaque centrifugation and brief hypotonic lysis of the remaining red blood cells, as described previously [21 ]. Until use, PMN were kept rocking at 4°C in phosphate-buffered saline (PBS) with glucose (125 mM NaCl, 2 mM NaH2PO4, 8 mM Na2HPO4, 5 mM KCl, 5 mM glucose), pH 7.4. All experiments were performed within 3 h of blood drawing.

Stimulus preparation
fMLP was dissolved in dry DMSO, aliquotted into glass vacutainers, and frozen at –20°C until used. Possible effects of the vehicle DMSO on pHi or [Ca2+]i were monitored at their experimental concentrations and were found to be absent. Human recombinant IL-8 was used as an alternative stimulus. Here, the carrier was PBS containing highly purified bovine serum albumin (BSA; final concentration, <0.01%), as recommended by the supplier (Sigma-Aldrich). Potential stimulation of pHi or [Ca2+]i by the vehicle was also examined and found to elicit a small {Delta}[Ca2+]i (<5%) equally in LAP- and in C-PMN.

Simultaneous [Ca2+]i and pHi measurements
PMN were loaded with the AM forms of the intracellular probes Indo-1 for [Ca2+]i and BCECF for intracellular pH, respectively, as described previously [8 , 9 ]. Fluorescence (Indo-1: {lambda}ex 350 nm, {lambda}em1 405, and {lambda}em2 485 nm; BCECF: {lambda}ex1 500 nm, {lambda}ex2 450 nm, and {lambda}em 530 nm) was measured continuously in a HitachiTM F-4500 fluorimeter equipped with stirring and thermostated at 37°C. The Indo-1 and BCECF fluorescences were exported into spreadsheet format for further statistical evaluation by ANOVA. The known dissociation constant of Indo-1 and the Grynkiewicz equation allowed calculation of [Ca2+]i from the Indo-1 ratios [23 ]. A calibration curve for BCECF fluorescence in PMN [6 , 7 ] was used to calculate pHi. We found that NifedipineTM exhibits some absorbance at 450 nm (data not shown); we therefore prepared a NifedipineTM dose curve and corrected our data for NifedipineTM absorbance at the concentration used.

Stimulus responses
PMN (2x106 per ml) were suspended in Krebs-Ringer phosphate [KRP; PBS-glucose supplemented with Ca2+ (0.9 mM) and Mg2+ (1.5 mM)] at 37°C with stirring for 2 min [21 ]. After this equilibration phase, the desired volume of fMLP or IL-8 stimulus was injected using a Hamilton syringe. The concentration of vehicle did not exceed 0.1% DMSO for fMLP or a final BSA concentration <0.01% for IL-8, respectively. When applicable, Ca2+ channel inhibitors were used and added to the cuvette prior to stimulation for the indicated length of time before the baseline was measured at t = 0.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Dose and time dependence of fMLP stimulation
Fluorimetric measurements of the PMN calcium response to stimulation were performed with 10–6–10–10 M fMLP and were found to be dose-dependent in PMN from LAP patients (n=5) and controls (n=5; Fig. 1 ). Although at fMLP concentrations of 10–10 and 10–9 M, a dose-proportional trend to an elevated maximal calcium response in LAP subjects was detectable (P≤0.06), it became statistically significant when the dose of fMLP was larger, i.e., at 10–8 M, which proved to be the saturating dose, yielding the highest response in both LAP- and C-PMN (P<0.01). The mean {Delta}[Ca2+]i in response to fMLP at the saturating concentration was 1280 nM for LAP-PMN, while cells of control subjects showed a 250-nM lower response (approximately 20%).



View larger version (14K):
[in this window]
[in a new window]
  		Figure 1. Mean cytoplasmic calcium response to fMLP: differences in the [Ca2+]i between LAP and control subjects were statistically significant at the saturating concentration of 10–8 M fMLP; *, P < 0.01 (ANOVA); n ≥ 5; error bars represent SD.

 
Dose and time dependence of IL-8 stimulation
The mean peak values of {Delta}[Ca2+]i of five LAP subjects versus five controls stimulated with 10–11 M IL-8 were higher (P=0.07; Fig. 2 ). The difference in the response between LAP- and C-PMN was statistically significant at 10–10 and 10–8 M IL-8 (P<0.01). At 10–10 M, the saturating concentration of IL-8, the maximal mean {Delta}[Ca2+]i was 880 nM for the LAP-PMN versus 630 nM (28% lower) for C-PMN.



View larger version (13K):
[in this window]
[in a new window]
  		Figure 2. Mean cytoplasmic calcium response to IL-8: differences in the [Ca2+]i between LAP and control subjects were statistically significant at 10–10 M and 10–8 M IL-8; *, P < 0.01 (ANOVA); n ≥ 5; error bars represent SD.

 
[Ca2+]i and cytoplasmic pH
As there is evidence that they are controlled via different mechanisms [9 , 24 ], simultaneous measurement of stimulus-induced cytoplasmic calcium and pH changes can yield important information about PMN intracellular signaling pathways [6 ]. In general, the cytosolic calcium responses to chemoattractants peak within 7–10 s after the stimulus is injected, released largely from intracellular stores [6 , 7 ]. The Ca2+ transient is accompanied by a rapid acidification attributable to PLD activation and consequent phosphatidic acid formation [7 , 20 , 24 ]. When LAP-PMN were stimulated with fMLP in the presence of extracellular Ca2+([Ca2+]out), a rapid acidification of the cytosol at the same rate but more extensive than C-PMN was detected (Fig. 3A ). Furthermore, although C-PMN exhibited the well-documented, rapid, subsequent decrease in [Ca2+]i, representing the redistribution of calcium within the PMN and its organelles, LAP-PMN exhibited a significantly slower and smaller one, implying impaired homeostasis of calcium in these cells.



View larger version (26K):
[in this window]
[in a new window]
  		Figure 3. (A) Stimulation of PMN with 10–8 M fMLP at 120 s in the presence of [Ca2+]out. Left ordinate: Indo-1 ratio (proportional to [Ca2+]i), LAP ({square}) versus control ({blacksquare}); right ordinate: percentage of initial F530 (proportional to pHi), LAP ({triangleup}) versus control ({blacktriangleup}). (B) Stimulation of PMN with 10–8 M fMLP at 135 s; [Ca2+]out was chelated with 5 µM EGTA 15 s before this stimulation (i.e., at 120 s; not shown). Left ordinate: Indo-1 ratio (proportional to [Ca2+]i), LAP ({square}) versus control ({blacksquare}); right ordinate: percentage of initial F530 (proportional to pHi), LAP ({triangleup}) versus control ({blacktriangleup}). Figure is representative of three independent experiments.

 
Both groups of PMN exhibited alkalinization of the cytoplasm via the well-documented Na+/H+antiport [25 , 26 ] after 30–40 s, but the LAP-PMN alkalinization was smaller. In addition, the rates of decrease in [Ca2+]i and increase in pHi were slower in the LAP- than in the C-PMN in response to 10–8 M fMLP in the presence of external Ca2+.

As recently shown by our group [6 ], an electrically neutral Ca2+/H+ exchanger exists in PMN, a finding here reconfirmed by the results reported for controls and extended to LAP-PMN. Thus, as shown in Figure 3B , when [Ca2+]out was chelated with 5 mM EGTA 15 s prior to fMLP stimulation, the maximal [Ca2+]i attained was slightly lower in LAP- and C-PMN, and the cytoplasmic acidification was stronger in both, in accordance with the action of the Ca2+/H+exchanger. Thus, the faster and greater acidification in the LAP-PMN is followed by their slower alkalinization and [Ca2+]i decrease after the high [Ca2+]i transient, implying a less-effective Ca2+/H+ exchange in these cells.

Modulation of PMN functions by cytokines and substance-P (SP)
A representative curve for the stimulation of LAP- and C-PMN is shown in Figure 4A . As indicated in Figure 4B , C-PMN were preincubated with the modulators IFN-{gamma}, IL-8, TNF-{alpha}, and SP at physiological concentrations for varying lengths of time (180, 600, 600, and 60 s, respectively), as described in the literature (for review, see Condliffe et al. [27 ]). Stimulation with 10–8 M fMLP then followed. Preincubation had no effect on C-PMN [Ca2+]i and pHi responses over a range of preincubation times or concentrations of these four modulators (1 and 100 ng/ml IFN-{gamma}; 10–12 and 10–9 M IL-8; 10 and 50 ng/ml TNF-{alpha}; and 10–9 as well as 10–7 M SP; data not shown). Figure 5 shows that these modulators also did not affect the maximal [Ca2+]i attained in LAP-PMN but that some did alter the internal redistribution that followed.



View larger version (25K):
[in this window]
[in a new window]
  		Figure 4. PMN calcium responses to 10–8 M fMLP. (A) LAP-PMN ({triangleup}; a); C-PMN (•; b). (B) Preincubation of control PMN with 10 ng/ml interferon-{gamma} (IFN-{gamma}) for 3 min (•; c); 10–11 M IL-8 for 10 min ({diamond}; d); 25 ng/ml tumor necrosis factor {alpha} (TNF-{alpha}) for 10 min (x; e); 10–8 M SP for 1 min ({square}; f). Go is representative of five independent experiments.

 


View larger version (13K):
[in this window]
[in a new window]
  		Figure 5. Modulation of calcium responses of LAP versus control PMN by various agents; *, P < 0.05 (ANOVA); n = 5; error bars represent SD.

 
SKF-96365-HCl and PMN
SKF-96365-HCl is an inhibitor of receptor-mediated Ca2+entry in PMN and other cells at concentrations that do not affect [Ca2+]i release [12 ]. At concentrations bracketing the 50% effective inhibitor concentration 50% (IC50; 12.9–15.6 µM), a small reduction of the fMLP-stimulated Indo-1 ratio was detected in LAP- and C-PMN (Fig. 6 ). Although the rate of internal redistribution of calcium was almost unaffected in LAP-PMN (Fig. 6A) , that in control subjects (Fig. 6B) , much more rapid in the absence of SKF-96365-HCl, became slower, mimicking LAP-PMN in the presence of the inhibitor.



View larger version (19K):
[in this window]
[in a new window]
  		Figure 6. PMN calcium responses to 10–8 M fMLP after 120 s incubation with the membrane Ca2+ channel inhibitor SKF-96365-HCl in KRP buffer. (A) LAP patients. (B) Control subjects: absence of the inhibitor ({blacktriangleup}; a); preincubation beginning at t = 0 with SKF-96365-HCl at 10 µM (x; b), 50 µM ({circ}; c), and 100 µM ({square}; d). Figures are representative of three separate experiments.

 
NifedipineTM and PMN
The calcium channel blocker NifedipineTM is reputed to block subcellular calcium release as well as membrane calcium channels [11 ]. When it was injected into the experimental suspension at t = 0, i.e., at the beginning of the 2-min incubation of LAP- or C-PMN in KRP, a NifedipineTM dose-dependent reduction in the Indo-1 ratio, corrected for NifedipineTM absorbance (see Materials and Methods), was observed (Fig. 7A ). Like SKF-96365-HCl, NifedipineTM slowed calcium replenishment in C-PMN (Fig. 7B) . Taken together, these findings imply that the redistribution within the cells is prolonged in C-PMN when the calcium fluxes are modulated by either of two membrane channel-blocking agents, SKF-96365-HCl or NifedipineTM.



View larger version (20K):
[in this window]
[in a new window]
  		Figure 7. PMN calcium responses to 10–8 M fMLP after 120 s incubation with NifedipineTM in KRP buffer. (A) LAP patients. (B) Control subjects: absence of the inhibitor ({blacktriangleup}; a); preincubation beginning at t = 0 with NifedipineTM at 10 µM ({square}; b), 50 µM ({circ}; c), and 100 µM (x; d). Figures are representative of five separate experiments.

 
VerapamilTM or DiltiazemTM and PMN
These two calcium channel blockers, even when used in concentrations up to fivefold higher than the IC50 dose [28 , 29 ], showed no inhibitory effects on the maximal calcium signal of PMN from patients or controls nor did they extend the Ca2+ redistribution in these PMN, as shown in Figure 8A for LAP-PMN and Figure 8B for C-PMN in the presence of VerapamilTM. The same absence of inhibitory effects was found for DiltiazemTM (data not shown).



View larger version (17K):
[in this window]
[in a new window]
  		Figure 8. PMN calcium responses to 10–8 M fMLP after 120 s incubation with VerapamilTM in KRP buffer. (A) LAP patients. (B) Control subjects: absence of the inhibitor ({blacktriangleup}; a); preincubation beginning at t = 0 with VerapamilTM at 10 µM ({square}; b), 50 µM ({circ}; c), and 100 µM (x; d). Figures are representative of three separate experiments.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
PMN play a key role in the host response during LAP infections [1 ] and are associated with the rapid tissue destruction in this severe periodontal disease [2 , 3 ]. Linkage between this form of periodontitis and acquired or inherited systemic diseases, as well as other syndromes characterized by leukocyte dysfunction, is also well-documented [4 ].

Our finding that the signaling process of LAP-PMN in response to chemotactic agents is altered with respect to pHi and [Ca2+]i signals agrees with and expands on previous reports of problems with the Ca2+ responses and Ca2+-related signaling pathways in LAP-PMN [19 ]. Those reports, using a calcium-buffering probe (Quin-2), suggested impaired signal transduction, leading to decreased influx of extracellular calcium. We here extend these findings to report an associated dysfunction in the cytoplasmic pH portion of PMN signal transduction [6 ]. Aberrant LAP-PMN responses have been variously attributed to later steps in the signaling pathways, including changes in the DAG/PKC pathway [13 ], calcium channel function [19 ], and abnormal influx putatively related to CIF [20 , 30 ]. We found that these dysfunctions in LAP involve Ca2+ and H+ signaling as well as the subsequent redistribution of these cations within the LAP-PMN and with their environment.

We showed here that the early, rapid stimulus responses to fMLP or IL-8 by LAP-PMN, as measured by changes in cytoplasmic [Ca2+] and pH, are larger in LAP-PMN than in C-PMN but occur at the same rate and like C-PMN, involve intracellular stores. In contrast, the redistribution of the rapidly released Ca2+ is significantly slower in LAP-PMN, implying a defect in Ca2+ passage through membrane(s) or in intracellular Ca2+ binding. The similarly slower alkalinization in LAP-PMN could reflect aberrant H+ passage through the membrane, e.g., through our recently described Ca2+/H+ channel [6 ], or to a defect in the well-documented Na+/H+ antiport [25 , 26 ].

In an attempt to delineate whether a membrane channel or the Ca2+ redistribution process was perturbed by LAP, we attempted to mimic the problem in C-PMN. A significantly slower C-PMN Ca2+ redistribution after fMLP could be documented if these control cells were preincubated with NifedipineTM, a Ca2+ channel inhibitor that is known to affect membrane channels and subcellular Ca2+ store release [11 ], or with SKF-96365-HCl, at concentrations reported to block membrane channels for Ca2+ while not varying intracellular Ca2+ store release. These drugs did not increase or decrease the rate of Ca2+ redistribution in LAP-PMN [12 ]. The combination of these observations with our finding that pHi responses are also aberrant in LAP-PMN points to but does not prove that LAP-PMN have a defective Ca2+/H+ channel in their membranes. Definitive proof must await the availability of specific inhibitors of that channel or of a patient in whom this defect has been shown by some other means.

The possibility has been raised that a sensitizing effect by "nonphysiological means" can elicit a detectable calcium response in PMN [31 ]. With respect to CIF functions, the most recent reports cite sphingosine-1 phosphate as a potential CIF, activated when intracellular calcium stores are released in human PMN [32 ]. Our studies address the question of Ca2+ signaling per se, in LAP- versus C-PMN but did not seek nor claim to identify the mediators that may be directly responsible for sensitization of the LAP-PMN (i.e., the specific factors or channels). They therefore do not address the existence or role of putative CIF.

Taken together, these findings imply that membrane-related components contribute strongly to the reported signal transduction defect in LAP-PMN. However, the elevated stimulus response in LAP-PMN has its source in an intracellular calcium release, which in view of the high DAG concentrations [16 , 17 ], may mean abnormal PLC or PLD activity or putatively slower processing of DAG itself [13 , 15 ], whether as a result of the membrane defect or independently of it. Additionally, the patient PMN appeared to have defective redistribution, a finding reinforced by our ability to create a similar impairment in C-PMN, when treated with the Ca2+ membrane channel inhibitors used here. It should be noted that the findings reported here relate specifically to the response of LAP- versus C-PMN to chemotactic agents and may not apply to the responses of PMN mediated by receptors for other stimuli. That is, although Seetoo et al. [9] showed that the calcium signal was not necessary for the oxidative burst as well as the lytic functions which are the bactericidal responsibility of PMN, these cellular functions are not initiated through chemotactic but through Fc, complement, and cytokine receptors. In summary, the experiments reported here indicate that severe infections in LAP patients may be attributable to impaired chemotactic signaling, but it does not necessarily follow that there is a defect in their capability to process and kill bacteria. Studies looking at these functions are in progress, since if there is indeed a membrane or membrane component-processing defect in LAP-PMN, it is quite likely to affect at least some of the functions mediated via Fc, complement, and cytokine receptors of PMN.


   ACKNOWLEDGEMENTS
 
We gratefully acknowledge the support of the Alexander von Humboldt Foundation (Feodor Lynen Program) as well as National Institutes of Health Grants DK31056, HL76463, DE13499, DE16191, and RR00533.

Received May 4, 2005; accepted May 5, 2005.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Kantarci, A., Oyaizu, K., Van Dyke, T. E. (2003) Neutrophil-mediated tissue injury in periodontal disease pathogenesis: findings from localized aggressive periodontitis J. Periodontol. 74,66-75[CrossRef][Medline]
  2. Van Dyke, T. E. (2002) The oral/dental/craniofacial complex as a model for inflammatory disease Compend. Contin. Educ. Dent. 23,465-468, 470, 472
  3. Kinane, D. F., Podmore, M., Murray, M. C., Hodge, P. J., Ebersole, J. (2001) Etiopathogenesis of periodontitis in children and adolescents Periodontol. 2000 26,54-91[CrossRef]
  4. Meyle, J., Gonzales, J. R. (2001) Influences of systemic diseases on periodontitis in children and adolescents Periondontol. 2000 26,92-112
  5. Sigusch, B., Eick, S., Pfister, W., Klinger, G., Glockmann, E. (2001) Altered chemotactic behavior of crevicular PMNs in different forms of periodontitis J. Clin. Periodontol. 28,162-167[CrossRef][Medline]
  6. Bernardo, J., Hartlaub, H., Yu, X., Long, H., Simons, E. R. (2002) Immune complex stimulation of human neutrophils involves a novel Ca2+/H+ exchanger that participates in the regulation of cytoplasmic pH: flow cytometric analysis of Ca2+/pH responses by subpopulations J. Leukoc. Biol. 72,1172-1179[Abstract/Free Full Text]
  7. Gewirtz, A. T., Seetoo, K. F., Simons, E. R. (1998) Neutrophil degranulation and phospholipase D activation are enhanced if the Na+/H+ antiport is blocked J. Leukoc. Biol. 64,98-103[Abstract]
  8. Lazzari, K. G., Proto, P. J., Simons, E. R. (1986) Simultaneous measurement of stimulus-induced changes in cytoplasmic Ca2+ and in membrane potential of human neutrophils J. Biol. Chem. 261,9710-9713[Abstract/Free Full Text]
  9. Seetoo, K. F., Schonhorn, J. E., Gewirtz, A. T., Zhou, M. J., McMenamin, M. E., Delva, L., Simons, E. R. (1997) A cytosolic calcium transient is not necessary for degranulation or oxidative burst in immune complex-stimulated neutrophils J. Leukoc. Biol. 62,329-340[Abstract]
  10. Brunkhorst, B. A., Lazzari, K. G., Strohmeier, G., Weil, G., Simons, E. R. (1991) Calcium changes in immune complex-stimulated human neutrophils. Simultaneous measurement of receptor occupancy and activation reveals full population stimulus binding but subpopulation activation J. Biol. Chem. 266,13035-13043[Abstract/Free Full Text]
  11. Levy, R., Nagauker-Shriker, O., Schlaeffer, F. (1996) Inhibited neutrophil functions in patients treated with nifedipine but not with Verapamil or Diltiazem Eur. J. Clin. Invest. 26,376-381[CrossRef][Medline]
  12. Merritt, J. E., Armstrong, W. P., Benham, C. D., Hallam, T. J., Jacob, R., Jaxa-Chamiec, A., Leigh, B. K., McCarthy, S. A., Moores, K. E., Rink, T. J. (1990) SK&F 96365, a novel inhibitor of receptor-mediated calcium entry Biochem. J. 271,515-522[Medline]
  13. Tyagi, S. R., Uhlinger, D. J., Lambeth, J. D., Champagne, C., Van Dyke, T. E. (1992) Altered diacylglycerol level and metabolism in neutrophils from patients with localized juvenile periodontitis Infect. Immun. 60,2481-2487[Abstract/Free Full Text]
  14. Kurihara, H., Murayama, Y., Warbington, M. L., Champagne, C. M., Van Dyke, T. E. (1993) Calcium-dependent protein kinase C activity of neutrophils in localized juvenile periodontitis Infect. Immun. 61,3137-3142[Abstract/Free Full Text]
  15. Gronert, K., Kantarci, A., Levy, B. D., Clish, C. B., Odparlik, S., Hasturk, H., Badwey, J. A., Colgan, S. P., Van Dyke, T. E., Serhan, C. N. (2004) A molecular defect in intracellular lipid signaling in human neutrophils in localized aggressive periodontal tissue damage J. Immunol. 172,1856-1861[Abstract/Free Full Text]
  16. Hurttia, H. M., Pelto, L. M., Leino, L. (1997) Evidence of an association between functional abnormalities and defective diacylglycerol kinase activity in peripheral blood neutrophils from patients with localized juvenile periodontitis J. Periodontal Res. 32,401-407[CrossRef][Medline]
  17. Leino, L., Hurttia, H., Peltonen, E. (1994) Diacylglycerol in peripheral blood neutrophils from patients with localized juvenile periodontitis J. Periodontal Res. 29,334-338[CrossRef][Medline]
  18. Fujita, T., Zawawi, K. H., Kurihara, H., Van Dyke, T. E. (2005) CD38 cleavage in fMLP- and IL-8-induced chemotaxis is dependent on p38 MAP kinase but independent of p44/42 MAP kinase Cell. Signal. 17,167-175[CrossRef][Medline]
  19. Daniel, M. A., McDonald, G., Offenbacher, S., Van Dyke, T. E. (1993) Defective chemotaxis and calcium response in localized juvenile periodontitis neutrophils J. Periodontol. 64,617-621[Medline]
  20. Shibata, K., Warbington, M. L., Gordon, B. J., Kurihara, H., Van Dyke, T. E. (2000) Defective calcium influx factor activity in neutrophils from patients with localized juvenile periodontitis J. Periodontol. 71,797-802[CrossRef][Medline]
  21. Luscinskas, F. W., Mark, D. E., Brunkhorst, B., Lionetti, F. J., Cragoe, E. J., Jr, Simons, E. R. (1988) The role of transmembrane cationic gradients in immune complex stimulation of human polymorphonuclear leukocytes J. Cell. Physiol. 134,211-219[CrossRef][Medline]
  22. Armitage, G. C. (1999) Development of a classification system for periodontal diseases and conditions Ann. Periodontol. 4,1-6[CrossRef][Medline]
  23. Grynkiewicz, G., Poenie, M., Tsien, R. Y. (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties J. Biol. Chem. 260,3440-3450[Abstract/Free Full Text]
  24. Gewirtz, A. T., Simons, E. R. (1997) Phospholipase D mediates Fc {gamma} receptor activation of neutrophils and provides specificity between high-valency immune complexes and fMLP signaling pathways J. Leukoc. Biol. 61,522-528[Abstract]
  25. Krump, E., Nikitas, K., Grinstein, S. (1997) Induction of tyrosine phosphorylation and Na+/H+ exchanger activation during shrinkage of human neutrophils J. Biol. Chem. 272,17303-17311[Abstract/Free Full Text]
  26. Sardet, C., Franchi, A., Pouyssegur, J. (1989) Molecular cloning, primary structure, and expression of the human growth factor-activatable Na+/H+ antiporter Cell 56,271-280[CrossRef][Medline]
  27. Condliffe, A. M., Kitchen, E., Chilvers, E. R. (1998) Neutrophil priming: pathophysiological consequences and underlying mechanisms Clin. Sci. (Lond.) 94,461-471[Medline]
  28. Zimmerman, J. J., Zuk, S. M., Millard, J. R. (1989) In vitro modulation of human neutrophil superoxide anion generation by various calcium channel antagonists used in ischemia-reperfusion resuscitation Biochem. Pharmacol. 38,3601-3610[CrossRef][Medline]
  29. Khalfi, F., Gressier, B., Brunet, C., Dine, T., Luyckx, M., Cazin, M., Cazin, J. C. (1996) Effects of calcium antagonist Diltiazem on leukocyte elastase and on reactive oxygen species production in human neutrophils Pharmacol. Res. 33,117-122[CrossRef][Medline]
  30. Randriamampita, C., Tsien, R. Y. (1993) Emptying of intracellular Ca2+ stores releases a novel small messenger that stimulates Ca2+ influx Nature 364,809-814[CrossRef][Medline]
  31. Bird, G. S., Bian, X., Putney, J. W., Jr (1995) Calcium entry signal? Nature 373,481-482[Medline]
  32. Itagaki, K., Hauser, C. J. (2003) Sphingosine 1-phosphate, a diffusible calcium influx factor mediating store-operated calcium entry J. Biol. Chem. 278,27540-27547[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Infect. Immun.Home page
J. M. Herrmann, J. Bernardo, H. J. Long, K. Seetoo, M. E. McMenamin, E. L. Batista Jr., T. E. Van Dyke, and E. R. Simons
Sequential Chemotactic and Phagocytic Activation of Human Polymorphonuclear Neutrophils
Infect. Immun., August 1, 2007; 75(8): 3989 - 3998.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0105023v1
78/3/612    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herrmann, J. M.
Right arrow Articles by Van Dyke, T. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herrmann, J. M.
Right arrow Articles by Van Dyke, T. E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS